epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Gut

How common are IBS and functional dyspepsia following acute gastroenteritis?

July 18, 2024

card-image

After a bout of gastroenteritis, 14.5% of individuals developed postinfection irritable bowel syndrome (PI-IBS) and 12.7% postinfection functional dyspepsia (PI-FD), with greater than fourfold increased odds for IBS and threefold for FD. Proteobacteria and SARS-CoV-2 may be behind the development of PI-IBS and PI-FD.

  • In this systematic review and meta-analysis, 47 observational studies comprising 28,170 subjects were used to examine the prevalence of IBS or FD after acute gastroenteritis with a >3 month follow-up. A random effects model was used to estimate prevalence and odds ratios (ORs) with 95% CIs.
  • Overall prevalence of PI-IBS and PI-FD were 14.5% and 12.7%, respectively. IBS persisted in 39.8% of subjects in the long-term (>5 years follow-up) after diagnosis. Individuals experiencing acute gastroenteritis had a significantly higher odds of IBS (OR, 4.3) and FD (OR, 3.0) than non-exposed controls.
  • PI-IBS was most associated with parasites (prevalence, 30.1%), but in only two studies, followed by bacteria (18.3%) and viruses (10.7%).
  • In available studies, Campylobacter was associated with the highest PI-IBS prevalence (20.7%) whereas Proteobacteria and SARS-CoV-2 yielded the highest odds for PI-IBS (both OR, 5.4). Prevalence of PI-FD was 10.0% for SARS-CoV-2 and 13.6% for bacteria (Enterobacteriaceae, 19.4%).

Source:

Porcari S, et al. (2024, July 16). Gut. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/39013599/

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information